Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis.
Experimental gram-negative sepsis was induced in the rat by Klebsiella pneumoniae. Although bacteria are susceptible to the treatment with the antibiotic Tobramycin, DIC could not be prevented. DIC was manifested by a leuko- and thrombocytopenia, decreases in fibrinogen and AT III and an increase of the aPTT. In this model the therapeutic treatment with human AT III was evaluated. To determine the optimal concentration of AT III a prestudy in a LPS induced DIC in the rat was performed. It was shown that a bolus i.v. injection of 500 U/kg improved survival and DIC, and was thus chosen for the Klebsiella sepsis model. The infectious load was adjusted to yield a mortality rate of 90-100% in the untreated Klebsiella group and a reduction to about 40-50% of the mortality rate by Tobramycin. It was found that AT III reduced mortality in the Klebsiella induced sepsis not only when given prophylactically but was effective even when administrated in a late stage of the DIC, i.e. 3 or 5 h post infection.
Dickneite
G
G
Research Laboratories, Behringwerke AG, Marburg/Lahn, Germany.
Pâques
E P
EP
D000818:Animals; D000990:Antithrombin III / Q000008:administration & dosage / Q000627:therapeutic use*; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D004195:Disease Models, Animal; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D007710:Klebsiella Infections / Q000150:complications / Q000188:drug therapy*; D007711:Klebsiella pneumoniae; D008070:Lipopolysaccharides / Q000633:toxicity; D051381:Rats; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use
D008070:Lipopolysaccharides; D000990:Antithrombin III; D014031:Tobramycin